The patent application, entitled "Containerized Medical Waste Treatment System and Related Method," focuses on the design and configuration of Aduromed's new standard, containerized MedClean Systems.
"The Aduromed team has invested significant time and effort into evolving
its operating model to meet the business and regulatory demands of the health
care institutions it targets," commented
The patent application also covers the specific protocol employed to accomplish sterilization in the company's autoclave subsystem. The protocol implements a sequence of differential heating and vacuum cycles designed to optimize efficacy and balance cycle time.
"The treatment protocol included in the patent is the result of research conducted with customers and industry experts that has yielded the most extensive body of work in the industry," added Mr. Grisanti. "This tested and validated protocol is a key component of our proprietary software and hardware platform, enabling MedClean solutions to meet and exceed the most demanding efficacy standards throughout all 50 states while providing the throughput required to economically address the highest volume generators of regulated medical waste. Our third-party validated efficacy results, combined with first in industry MedClean container configurations, are expected to accelerate adoption of Aduromed's solutions."
About Aduromed
Aduromed Industries, Inc., through its wholly-owned subsidiary, Aduromed Corporation, is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. Aduromed's flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste.
Aduromed was founded in 1997 with corporate headquarters, research and
development, and distribution facilities located in
Statements about our future expectations are "forward-looking statements"
within the meaning of applicable Federal Securities Laws, and are not
guarantees of future performance. When used herein, the words "may," "will,"
"should," "anticipate," "believe," "appear," "intend," "plan," "expect,"
"estimate," "approximate," and similar expressions are intended to identify
such forward-looking statements. These statements involve risks and
uncertainties inherent in our business, including those set forth in our most
recent Annual Report on Form 10-K for the year ended
SOURCE Aduromed Industries, Inc.